After the treatment of liraglutide and semaglutide, more corpus luteum and fewer cystic follicles were observed in the ovarian tissue of PCOS mice, and the disorders of the estrous cycle were improved, which indicated that GLP-1R agonists reversed pathological abnormalities in ovarian; additionally, GLP-1R agonists also improved the abnormal expression of ovarian steroidogenic enzymes in PCOS mice [212]. Here, GLP1R is linked to polycystic ovary syndrome.